Core Viewpoint - The company, Morning Bio (300138.SZ), anticipates significant growth in its financial performance for the first half of 2025, driven primarily by the recovery in its cottonseed business and steady growth in its plant extraction segment [1][2]. Financial Performance Summary - The company expects to achieve revenue between 3.46 billion to 3.76 billion yuan, reflecting a year-on-year change of -0.89% to 7.71% [1]. - The projected net profit attributable to shareholders is estimated to be between 202 million to 232 million yuan, indicating a substantial year-on-year increase of 102.33% to 132.38% [1]. - The expected non-recurring net profit ranges from 174 million to 204 million yuan, with a remarkable growth rate of 117.40% to 154.88% compared to the previous year [1]. Business Segment Performance - The recovery in the cottonseed business is identified as the main factor influencing the company's performance, transitioning from losses to profitability due to improved market conditions [1]. - The plant extraction business, including products like chili red, chili essence, and steviol glycosides, has also contributed to the overall profit growth, with significant year-on-year increases in gross profit [1]. Strategic Insights - The company has committed to a locked-in operating model, which has effectively mitigated risks associated with price fluctuations in the cottonseed market, leading to a turnaround in profitability [1][2]. - The company anticipates that high prices for cottonseed protein and the implementation of new standards for lutein will provide ongoing growth momentum in the second half of the year [2].

4月27日晚间，新赛股份（600540）披露2024年年报，报告期公司皮棉、棉籽、棉油、棉蛋白等销售数 量较上年同期增加，报告期公司实现营业收入16.36亿元，较上年同期增长68.42%；但是受棉、棉籽等 市场需求减弱及国际环境影响和相关产品计提存货跌价准备，实现归属于上市公司股东的净利润-2.44 亿元。 资料显示，新赛股份自成立以来坚持以棉花全产业链为公司主业，以矿业为辅，以资本运营为支持的总 体发展战略。 在棉花产业链方面，公司深耕于棉花初加工行业已多年，生产的皮棉产品的质量不断提高，目前均达到 了国家标准，"新赛"牌皮棉畅销疆内、外；棉纱可作为机织用纱，也可作为针织用纱，其中精梳纱可以 用来生产质量要求较高的纺织品，如高档汗衫、细号府绸等，棉纱还可以生产独特工业用的电工黄蜡 布、轮胎帘子布、高速缝纫线和刺绣线等；棉籽蛋白接近于大豆及其它谷物蛋白，是一种高质量的蛋白 来源，是动物饲料的良好基料，可替代进口高浓缩大豆蛋白及进口鱼粉；脱酚棉籽油是食用油的一种， 也可作为食用调和油的基油。同时，公司采用先进的生产工艺，主产品脱酚棉籽浓缩蛋白的蛋白含量达 60%以上，同时较大程度降低了棉籽中游离棉酚的含量，克服 ...

证券代码：300138 证券简称：晨光生物 晨光生物科技集团股份有限公司 | 性。受豆粕等大宗农产品行情影响，今年以来棉籽加工行 | | --- | | 业行情回暖，公司把握市场机遇，严格执行对锁的经营模 | | 式，2025 年一季度棉籽类业务经营同比显著改善。 | | 7、公司短期借款增长比较多的原因？ | | 2025 年一季度，为准备下阶段原料采购所需资金及置 | | 换前期融资，公司新增了短期融资。因融资资金到位、计 | | 划偿还的银行借款尚未到期并偿还，一季度末账面短期借 | | 款规模增长较多，相应货币资金也大幅增长。 | | 8、2025 年公司在保健食品和中药方面有哪些新规划？ | | 保健食品 2024 年收入约 1.6 亿元，目前正在建设新的 | | 生产车间，新产能投产能够支撑公司保健食品业务规模继 | | 续增长。目前保健食品业务以 OEM 代工为主，2025 年将致 | | 力于研发新的功效明确、有晨光特色的产品，争取以卓越 | | 的品质和服务不断扩大在行业内的影响力。 | | 中成药业务仍在早期发展阶段，2024 年收入突破 1000 | | 万元，2025 年重点将放单方大 ...